Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit Rampal, Prithviraj Bose, Elizabeth O. Hexner, Moshe Talpaz, Laura C. Michaelis, Prioty Islam, Ronan T. Swords, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 657.

https://doi.org/10.1182/blood-2024-203719

Published: 2024

Journal Articles

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Blood (2024) 144 (Supplement 1): 384.

https://doi.org/10.1182/blood-2024-203344

Published: 2024

Journal Articles

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Blood (2024) 144 (Supplement 1): 380.

https://doi.org/10.1182/blood-2024-204010

Published: 2024

Journal Articles

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Blood (2024) 144 (Supplement 1): 909.

https://doi.org/10.1182/blood-2024-202659

Published: 2024

Journal Articles

Inconsistent Reporting and Definition of Time-to-Event Endpoints in CAR T Clinical Trials: A Review of the Literature and a Call for Harmonization

Connor B Grady, Yimei Li, Shannon L. Maude, Elizabeth O. Hexner, Noelle Frey, David L. Porter, Wei-Ting Hwang

Blood (2024) 144 (Supplement 1): 7805.

https://doi.org/10.1182/blood-2024-202597

Published: 2024

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression

Ying WANG, Alicia Huaze Li, Ruqayyah sanders-Braggs, Yan Zhou, Mimi Chen, Tien Bui, Hongfa Zhu, Nasheed Hossain, Jonathan Soboloff, John Elrod, Elizabeth O. Hexner, Yi Zhang

Blood (2024) 144 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2024-212312

Published: 2024

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Blood (2024) 144 (9): 1010–1021.

https://doi.org/10.1182/blood.2024025106

Published: 2024

Includes: Supplemental data

Journal Articles

Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD

Ying Wang, Shan He, Gennaro Calendo, Tien Bui, Yuanyuan Tian, Che Young Lee, Yan Zhou, Xin Zhao, Ciril Abraham, Wenbin Mo, Mimi Chen, Ruqayyah Sanders-Braggs, Jozef Madzo, Jean-Pierre Issa, Elizabeth O. Hexner, David L. Wiest, Ran Reshef, Hai-Hui Xue, Yi Zhang

Blood (2024) 143 (2): 166–177.

https://doi.org/10.1182/blood.2023021126

Published: 2024

Includes: Supplemental data

Journal Articles

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Blood (2023) 142 (Supplement 1): 955.

https://doi.org/10.1182/blood-2023-180185

Published: 2023

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Blood (2023) 142 (Supplement 1): 776.

https://doi.org/10.1182/blood-2023-181900

Published: 2023

Journal Articles

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

Matthew P Connor, Neeharika Prathapa, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander Perl, David L. Porter, Arlene Zeringue, Joseph H. Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok

Blood (2023) 142 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2023-179383

Published: 2023

Journal Articles

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Blood (2023) 142 (Supplement 1): 3576.

https://doi.org/10.1182/blood-2023-182300

Published: 2023

Journal Articles

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Blood (2023) 142 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2023-186978

Published: 2023

Journal Articles

Dual Functions of Mitochondrial Calcium Uniporter in T Cell Alloimmunity

Ying WANG, Alicia Huaze Li, Ruqayyah sanders-Braggs, Yan Zhou, Mimi Chen, Tien Bui, Hongfa Zhu, Jonathan Soboloff, John Elrod, Elizabeth O Hexner, Yi Zhang

Blood (2023) 142 (Supplement 1): 4787.

https://doi.org/10.1182/blood-2023-190563

Published: 2023

Journal Articles

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Ashley D Hadjis, Griffin W White, Christopher Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine Lai, Andrew H Matthews, Mary Ellen Martin, Daria V Babushok, Alexander Perl, David L. Porter, Alison W Loren, Keith W Pratz, Selina M Luger, Shannon R McCurdy

Blood (2023) 142 (Supplement 1): 376.

https://doi.org/10.1182/blood-2023-188978

Published: 2023

Journal Articles

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Seiichi Villalona, Xin Wang, Peter Gabriel, Abigail Doucette, Shannon R McCurdy, Alexander Perl, Selina M Luger, Noelle V. Frey, Ximena Jordan Bruno, Elizabeth O Hexner, Daria V Babushok, David L. Porter, Alison W Loren, Keith W Pratz, Catherine Lai

Blood (2023) 142 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2023-178247

Published: 2023

Journal Articles

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1022–1024.

https://doi.org/10.1182/blood-2022-168036

Published: 2022

NARROW

A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Inconsistent Reporting and Definition of Time-to-Event Endpoints in CAR T Clinical Trials: A Review of the Literature and a Call for Harmonization

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD

Evolving Racial/Ethnic Disparities in AML Survival in the Novel Therapy Era: Real-World Evidence of Improved Survival in Older Patients with the Largest Improvement in Non-Hispanic Black Patients

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Flares of Acute Graft-Versus-Host Disease: Mount Sinai Acute Gvhd International Consortium (MAGIC) Study

Hypomethylating Agents Are Associated with High Rates of Hematologic Toxicity in Patients with Secondary MDS/AML That Develops after Acquired Aplastic Anemia

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Comparing Cairo Bishop and Howard Criteria for Identifying Clinically Meaningful Tumor Lysis Syndrome Among Acute Myeloid Leukemia Patients Treated with Venetoclax and Hypomethylating Agents: A Single Center Experience

Dual Functions of Mitochondrial Calcium Uniporter in T Cell Alloimmunity

Frail and Pre-Frail Older Adults with Acute Myeloid Leukemia Have Inferior Survival Due to Higher Rates of Disease-Related Deaths

Patient-Reported Outcome Measures Associated with Overall Survival and Acute Care Use in Patients with Newly Diagnosed Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Acute Lymphoblastic Leukemia

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only